A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors.

Inigo Espinosa, MD a, Cheng-Han Lee, MD, PhDa, Mi Kyung Kim, MD, PhD a, Bich-Tien Rouse, MSa, Subbaya Subramanian, PhD a, Kelli Montgomery a, Sushama Varma, MS a Christopher L. Corless, MD, PhD b, Michael C. Heinrich, MD b, Kevin S. Smith, PhDa, Zhong Wang, PhDa, Brian Rubin MD, PhDc, Torsten O Nielsen MD, PhDd, Robert S Seitz MDe, Douglas T Ross, MD, PhDe , Robert B West, MD, PhDa, Michael L. Cleary, MDa, and Matt van de Rijn, MD, PhDa

 

Home
Home
Figures
Figures
Images
Images
Tables
Tables
Methods
Methods
Authors
Authors
Web Portal
Web portal

Tables

Table 1:  Mesenchymal tumors other than GIST included in the study.

Tumors                                                                            

Number of cases

Alveolar soft part sarcoma

2

Phyllodes tumor

2

Pleomorphic liposarcoma

3

Epithelioid sarcoma

3

Fibrosarcoma                      

3

Chondrosarcoma

3

Inflammatory pseudotumor

5

Clear cell sarcoma

7

DSRCT*

7

Dedifferentiated liposarcoma

10

Myxoid liposarcoma

10

Ewing/PNET

10

Desmoplastic melanoma

10

Well differentiated liposarcoma

11

Extraskeletal myxoid chondrosarcoma

11

Low grade fibromyxoid sarcoma

11

Fibroadenoma

11

Epithelioid hemangioendothelioma

12

Endometrial stroma sarcoma

13

Rhabdomyosarcoma

13

Angiosarcoma

14

Osteosarcoma

14

Dermatofibrosarcoma protuberans

20

Solitary fibrous tumor

21

Leiomyoma

22

Desmoid fibromatosis  

35

Synovial sarcoma

44

Schwanoma

46

Neurofibroma

55

Malignant peripheral nerve sheath tumor

86

Undifferentiated sarcoma

87

Leiomyosarcoma

334

*Desmoplastic small round cell tumor

 

Table 2: Clinicopathologic features of GIST cases.

Total number of patients:

 

447

Age (n=341; 3-95 y;median:59)

 

 

 

<18 years

9 (3%)

 

≥18y <40y

31 (9%)

 

≥40y <60y

139 (41%)

 

≥60y

162 (48%)

Sex (n=357)

 

 

 

Female

179 (50%)

 

Male

178 (50%)

Size (n=303)

 

 

 

≤2cm

21 (7%)

 

>2cm ≤5cm

94 (31%)

 

>5cm≤10cm

96 (32%)

 

 >10cm

92 (30%)

Location (n=337)

 

 

 

Stomach

179 (53%)

 

Small bowel

101 (30%)

 

Large bowel

27 (8%)

 

EGIST*

24 (7%)

 

Esophagus

3 (1%)

 

Gallbladder

3 (1%)

Risk (n=70)

 

 

 

Very low

5 (7%)

 

Low

30 (43%)

 

Intermediate

10 (14%)

 

High

25 (36%)

* Extragastrointestinal GIST.

 

 
 
 
                      [ Home | Figures | Images | Tables | Methods | WebPortal | Authors]